OBJECTIVE: To assess whether changes in antemortem MRI brain volume measurements are valid predictors of subsequent Alzheimer disease (AD) pathology. METHODS: Thirty-nine subjects, 15 nondemented and 24 with cognitive impairment, were followed until death. Regional postmortem measures of senile plaque (SP) and neurofibrillary tangle (NFT) severity were examined in relationship to cross-sectional and longitudinal volumetric measurements obtained from antemortem MRI. RESULTS: Total brain volume change over time was related to the accumulation of cortical NFT. The rate of ventricular CSF volume increase was related to both cortical NFT and SP. The last hippocampal volume prior to death was related to hippocampal NFT burden; the rate of hippocampal volume atrophy was not related to hippocampal NFT pathology. These significant relationships continue to exist when all nondemented subjects are excluded from analysis. In subjects with cognitive impairment, the best predictor of cortical NFT and SP is the rate of ventricular volume increase. Excluding subjects with long duration between MRI and death did not appreciably alter results. CONCLUSIONS: MRI volumes measured over time are valid biomarkers of pathologic progression of AD across a range of antemortem clinical states. The rate of ventricular volume enlargement can be used to monitor disease progression or response to treatment in future clinical trials that are targeted at NFT and SP pathology.
OBJECTIVE: To assess whether changes in antemortem MRI brain volume measurements are valid predictors of subsequent Alzheimer disease (AD) pathology. METHODS: Thirty-nine subjects, 15 nondemented and 24 with cognitive impairment, were followed until death. Regional postmortem measures of senile plaque (SP) and neurofibrillary tangle (NFT) severity were examined in relationship to cross-sectional and longitudinal volumetric measurements obtained from antemortem MRI. RESULTS: Total brain volume change over time was related to the accumulation of cortical NFT. The rate of ventricular CSF volume increase was related to both cortical NFT and SP. The last hippocampal volume prior to death was related to hippocampal NFT burden; the rate of hippocampal volume atrophy was not related to hippocampal NFT pathology. These significant relationships continue to exist when all nondemented subjects are excluded from analysis. In subjects with cognitive impairment, the best predictor of cortical NFT and SP is the rate of ventricular volume increase. Excluding subjects with long duration between MRI and death did not appreciably alter results. CONCLUSIONS: MRI volumes measured over time are valid biomarkers of pathologic progression of AD across a range of antemortem clinical states. The rate of ventricular volume enlargement can be used to monitor disease progression or response to treatment in future clinical trials that are targeted at NFT and SP pathology.
Authors: Prashanthi Vemuri; Gyorgy Simon; Kejal Kantarci; Jennifer L Whitwell; Matthew L Senjem; Scott A Przybelski; Jeffrey L Gunter; Keith A Josephs; David S Knopman; Bradley F Boeve; Tanis J Ferman; Dennis W Dickson; Joseph E Parisi; Ronald C Petersen; Clifford R Jack Journal: Neuroimage Date: 2010-12-31 Impact factor: 6.556
Authors: Owen T Carmichael; Lewis H Kuller; Oscar L Lopez; Paul M Thompson; Rebecca A Dutton; Allen Lu; Sharon E Lee; Jessica Y Lee; Howard J Aizenstein; Carolyn C Meltzer; Yanxi Liu; Arthur W Toga; James T Becker Journal: Alzheimer Dis Assoc Disord Date: 2007 Jan-Mar Impact factor: 2.703
Authors: D Erten-Lyons; R L Woltjer; H Dodge; R Nixon; R Vorobik; J F Calvert; M Leahy; T Montine; J Kaye Journal: Neurology Date: 2009-01-27 Impact factor: 9.910
Authors: Yi-Yu Chou; Natasha Leporé; Christina Avedissian; Sarah K Madsen; Neelroop Parikshak; Xue Hua; Leslie M Shaw; John Q Trojanowski; Michael W Weiner; Arthur W Toga; Paul M Thompson Journal: Neuroimage Date: 2009-02-21 Impact factor: 6.556
Authors: Susanne G Mueller; Michael W Weiner; Leon J Thal; Ronald C Petersen; Clifford R Jack; William Jagust; John Q Trojanowski; Arthur W Toga; Laurel Beckett Journal: Alzheimers Dement Date: 2005-07 Impact factor: 21.566
Authors: Sean M Nestor; Raul Rupsingh; Michael Borrie; Matthew Smith; Vittorio Accomazzi; Jennie L Wells; Jennifer Fogarty; Robert Bartha Journal: Brain Date: 2008-07-11 Impact factor: 13.501
Authors: Clifford R Jack; David S Knopman; William J Jagust; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; John Q Trojanowski Journal: Lancet Neurol Date: 2010-01 Impact factor: 44.182